Twist Bioscience Corp's (NASDAQ:TWST) Chief Financial Officer, Adam Laponis, recently sold shares of the company's common stock, transactions that are part of the company's tax withholding obligations related to restricted stock units. The sale, as reported in a recent SEC filing, involved a total of 856 shares at an average price of $41.812 per share, amounting to over $35,791.
The shares sold by Laponis are to cover tax withholdings upon the vesting of Restricted Stock Units, a process mandated by Twist Bioscience's equity incentive plans. This "sell to cover" transaction is not a discretionary trade but a required action to satisfy tax obligations. Following this transaction, Laponis continues to hold 73,397 shares in the company, which includes shares acquired under the company's Employee Stock Purchase Plan.
Investors often monitor insider transactions for insights into a company's financial health and the confidence that executives have in their firm's prospects. In this case, the transaction reflects a routine financial management practice rather than a strategic shift in investment by the CFO.
Twist Bioscience specializes in synthetic DNA and is based in South San Francisco, California. The company's stock trades on the NASDAQ under the ticker symbol TWST.
In other recent news, Twist Bioscience Corporation has been making significant strides. The company reported a robust 28% year-over-year growth in revenue for the fiscal third quarter of 2024, totaling $81.5 million. The gross margin also improved significantly to 43.3%, with a target to exceed 50% by the end of fiscal 2025. Twist Bioscience anticipates a 27% increase in total revenue for fiscal 2024 year-over-year, with projected Q4 revenue between $82 million and $83 million.
Baird has maintained an Outperform rating on Twist Bioscience, based on the company's Express Genes service's elevated pricing premiums. The firm's analysis suggests that the sustained high premiums could indicate strong demand for the company's synthetic genes offering.
In terms of product development, Twist Bioscience has expanded its DNA synthesis capabilities, now offering gene fragments up to 5.0 kilobases in length. Additionally, the company launched a Transaminase Enzyme Screening Kit in collaboration with bitBiome Inc., which aims to provide a more environmentally friendly alternative for synthesizing chiral amines, key components in drug manufacturing. These are recent developments in Twist Bioscience's operations and strategic initiatives.
InvestingPro Insights
To provide additional context to Adam Laponis's recent stock transaction, let's examine some key financial metrics and insights from InvestingPro for Twist Bioscience Corp (NASDAQ:TWST).
According to InvestingPro data, Twist Bioscience has a market capitalization of $2.61 billion. The company has shown strong revenue growth, with a 25.37% increase over the last twelve months as of Q3 2024, reaching $295.21 million. This growth trend is even more pronounced in the quarterly figures, with a 27.81% revenue increase in Q3 2024.
Despite this top-line growth, profitability remains a challenge for Twist Bioscience. An InvestingPro Tip indicates that the company is not profitable over the last twelve months, which is reflected in its negative operating income of -$189.94 million for the same period. This aligns with another InvestingPro Tip suggesting that analysts do not anticipate the company to be profitable this year.
On a positive note, Twist Bioscience's financial position appears stable in the short term. An InvestingPro Tip highlights that the company's liquid assets exceed its short-term obligations, providing some financial flexibility.
Investors should note that Twist Bioscience's stock has shown significant volatility, with an InvestingPro Tip pointing out that stock price movements are quite volatile. This is evidenced by the impressive 116.25% price total return over the past year, despite a 20.64% decline in the last three months.
For those interested in a deeper analysis, InvestingPro offers 8 additional tips for Twist Bioscience, providing a more comprehensive view of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.